PQ912

DRUG3 trials

Sponsors

Vivoryon Therapeutics N.V.

Conditions

Alzheimer DiseaseEarly Alzheimers DiseaseHealthy VolunteersMild Cognitive Impairment Due to ADPharmacologic Action

Phase 1

Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole

CompletedNCT02190708

Vivoryon Therapeutics N.V.Healthy Volunteers, Pharmacologic Action

Start: 2014-06-30End: 2014-08-31Updated: 2015-10-21

Phase 2

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

TerminatedNCT03919162

Vivoryon Therapeutics N.V.Alzheimer Disease

Start: 2021-11-15End: 2024-08-12Updated: 2025-12-12

A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

CompletedNCT04498650

Vivoryon Therapeutics N.V.Early Alzheimers Disease, Mild Cognitive Impairment Due to AD

Start: 2020-07-06End: 2024-01-12Updated: 2024-03-12

Related Papers

#1174 Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent phase 2 studies

Nephrology Dialysis Transplantation2025-10-01

Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease

Journal of Alzheimer s Disease2024-10-188 citations

VIVIAD, A Phase 2b Study Investigating Varoglutamstat in Patients with MCI or Mild AD: Analysis of Baseline Cognition Data

Alzheimer s & Dementia2023-12-01

VIVIAD, A Phase 2b Study Investigating Varoglutamstat in Patients with MCI and Mild AD: Dose Selection and Interim Safety Results

Alzheimer s & Dementia2022-12-01

A novel, efficient and seamless Phase 2A‐2B design to test varoglutamstat in early AD: the VIVA‐MIND study

Alzheimer s & Dementia2022-12-01

Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD.

2021-08-2328 citations